May 15, 2020
FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors
Apr 30, 2020
Data From EMD Serono at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
Apr 09, 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Jan 23, 2020
Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)
Jan 09, 2020
Blueprint Medicines Announces FDA Approval of AYVAKIT(TM) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Nov 07, 2019
Global Neuroendocrine Tumors (NETs) Market Report 2019
Oct 28, 2019
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Oct 28, 2019
Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Oct 15, 2019
Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) for the First-Line Treatment of Adults with Advanced Renal Cell Carcinoma
Sep 27, 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Sep 20, 2019
Bayer data at ESMO 2019 highlights innovation in cancer research
Sep 20, 2019
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Aug 07, 2019
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Jul 09, 2019
CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST
Jun 19, 2019
Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
Jun 14, 2019
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Jun 11, 2019
Neuroendocrine Tumor Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Jun 01, 2019
Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib
May 14, 2019
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Feb 16, 2019
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine